Live Earnings Conference Call: LENZ Therapeutics will host a live Q1 2025 earnings call on May 7, 2025 at 4:30PM ET. Follow this link to get details and listen to LENZ Therapeutics' Q1 2025 earnings call when it goes live. Get details. LENZ Therapeutics (LENZ) News Today $26.28 +0.40 (+1.53%) As of 12:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care ConferenceMay 6 at 4:30 PM | globenewswire.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Purchased by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD boosted its holdings in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 83.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 822,957 shares of the company'May 4 at 4:10 AM | marketbeat.comRenaissance Technologies LLC Sells 23,900 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)Renaissance Technologies LLC lowered its stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 48.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,366 shares of the company's stock afteMay 4 at 3:27 AM | marketbeat.comSamsara BioCapital LLC Lowers Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Samsara BioCapital LLC lessened its holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 18.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 986,981 shares of the company's stock after selling 221,492 shares during theMay 2, 2025 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Position Lessened by Boothbay Fund Management LLCBoothbay Fund Management LLC decreased its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 26.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,746 shares of the company's stocMay 1, 2025 | marketbeat.comLENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025April 30, 2025 | globenewswire.comRock Springs Capital Management LP Acquires New Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Rock Springs Capital Management LP purchased a new position in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 29,305 shares of the company's stockApril 23, 2025 | marketbeat.comLENZ Therapeutics' (LENZ) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $38.00 price target on shares of LENZ Therapeutics in a research note on Wednesday.April 18, 2025 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: 908 Devices (MASS), LENZ Therapeutics (LENZ) and Johnson & Johnson (JNJ)April 17, 2025 | markets.businessinsider.comLENZ Therapeutics (NASDAQ:LENZ) Shares Gap Up - Should You Buy?LENZ Therapeutics (NASDAQ:LENZ) Shares Gap Up - Here's WhyApril 17, 2025 | marketbeat.comBank of America Securities Keeps Their Buy Rating on LENZ Therapeutics (LENZ)April 17, 2025 | markets.businessinsider.comLENZ Therapeutics (LENZ) Receives a Buy from TD CowenApril 17, 2025 | markets.businessinsider.comLENZ Therapeutics (NASDAQ:LENZ) Stock Price Up 8.3% - Still a Buy?LENZ Therapeutics (NASDAQ:LENZ) Stock Price Up 8.3% - Time to Buy?April 16, 2025 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Now Covered by Analysts at Piper SandlerPiper Sandler started coverage on LENZ Therapeutics in a report on Monday. They issued an "overweight" rating and a $51.00 price target for the company.April 16, 2025 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Bought by Vanguard Group Inc.Vanguard Group Inc. boosted its holdings in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 5.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,178,447 shares of the company's stockApril 15, 2025 | marketbeat.comLenz Therapeutics assumed with an Overweight at Piper SandlerApril 14, 2025 | markets.businessinsider.comLENZ Therapeutics (LENZ) Receives a Buy from Piper SandlerApril 14, 2025 | markets.businessinsider.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Buy" by BrokeragesShares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have received a consensus rating of "Buy" from the eight research firms that are covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy ratApril 14, 2025 | marketbeat.comnew option listings on April 9thApril 9, 2025 | markets.businessinsider.comLENZ Therapeutics (NASDAQ:LENZ) Shares Down 8.5% - Here's What HappenedLENZ Therapeutics (NASDAQ:LENZ) Trading Down 8.5% - Time to Sell?April 9, 2025 | marketbeat.comLENZ Therapeutics: Freedom From Reading GlassesApril 7, 2025 | seekingalpha.comLenz Therapeutics files $500M mixed securities shelfApril 5, 2025 | markets.businessinsider.comLenz Therapeutics files to sell 13.07M shares of common stock for holdersApril 5, 2025 | markets.businessinsider.comLENZ Therapeutics files to sell 13M shares of common stock for holdersApril 4, 2025 | msn.comLENZ Therapeutics (NASDAQ:LENZ) Shares Gap Up - What's Next?LENZ Therapeutics (NASDAQ:LENZ) Shares Gap Up - Here's What HappenedApril 4, 2025 | marketbeat.comClimb Bio Appoints Seasoned Biotech Leaders to Board of DirectorsApril 1, 2025 | markets.businessinsider.com18,900 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Purchased by Swiss National BankSwiss National Bank acquired a new stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 18,900 shares of the company's stock, valued at approximatelyMarch 31, 2025 | marketbeat.comLENZ Therapeutics Stock Is Attractive Before PDUFAMarch 27, 2025 | seekingalpha.comBrokers Issue Forecasts for LENZ Q2 EarningsLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 EPS estimates for LENZ Therapeutics in a research note issued to investors on Thursday, March 20th. HC Wainwright analyst M. Caufield anticipates that the company will earn ($0.60) perMarch 24, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for LENZ Q1 Earnings?LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for LENZ Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. Leerink Partnrs analyst M. Goodman anticipates thMarch 24, 2025 | marketbeat.comWilliam Blair Issues Negative Outlook for LENZ EarningsLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities research analysts at William Blair reduced their Q1 2025 earnings estimates for shares of LENZ Therapeutics in a research note issued to investors on Thursday, March 20th. William Blair analyst L. Hanbury-Brown now forecasts that theMarch 24, 2025 | marketbeat.comFY2026 Earnings Forecast for LENZ Issued By William BlairLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at William Blair issued their FY2026 earnings per share estimates for shares of LENZ Therapeutics in a research report issued to clients and investors on Thursday, March 20th. William Blair analyst L. Hanbury-Brown forecastMarch 22, 2025 | marketbeat.comQ1 Earnings Forecast for LENZ Issued By HC WainwrightLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of LENZ Therapeutics in a research note issued on Thursday, March 20th. HC Wainwright analyst M. Caufield expects that the company will post earnings of ($0.52)March 22, 2025 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Stock Price Expected to Rise, Citigroup Analyst SaysCitigroup lifted their target price on LENZ Therapeutics from $44.00 to $47.00 and gave the stock a "buy" rating in a research report on Thursday.March 21, 2025 | marketbeat.comEarnings call transcript: LENZ Therapeutics Q4 2024 shows innovation driveMarch 21, 2025 | uk.investing.comLENZ THERAPEUTICS Earnings Results: $LENZ Reports Quarterly EarningsMarch 21, 2025 | nasdaq.comLenz Therapeutics price target raised to $38 from $37 at BofAMarch 21, 2025 | markets.businessinsider.comLenz Therapeutics price target raised to $47 from $44 at CitiMarch 21, 2025 | markets.businessinsider.comLENZ Therapeutics (NASDAQ:LENZ) Posts Earnings Results, Misses Expectations By $0.05 EPSLENZ Therapeutics (NASDAQ:LENZ - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.05).March 20, 2025 | marketbeat.comLENZ Therapeutics, Inc.: LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate HighlightsMarch 20, 2025 | finanznachrichten.deLENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | seekingalpha.comLenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progressMarch 19, 2025 | msn.comLENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate HighlightsMarch 19, 2025 | globenewswire.comLENZ Therapeutics (NASDAQ:LENZ) Shares Gap Up - Still a Buy?LENZ Therapeutics (NASDAQ:LENZ) Shares Gap Up - Should You Buy?March 19, 2025 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Rating of "Buy" by AnalystsLENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) has earned an average recommendation of "Buy" from the seven research firms that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buyMarch 19, 2025 | marketbeat.comTD Cowen Begins Coverage on LENZ Therapeutics (NASDAQ:LENZ)TD Cowen initiated coverage on LENZ Therapeutics in a research report on Tuesday. They set a "buy" rating and a $60.00 price objective for the company.March 19, 2025 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 6.1% - Here's What HappenedLENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 6.1% - Time to Sell?March 18, 2025 | marketbeat.comLenz Therapeutics initiated with a Buy at TD CowenMarch 18, 2025 | markets.businessinsider.comLENZ Therapeutics (NASDAQ:LENZ) Sees Strong Trading Volume - What's Next?LENZ Therapeutics (NASDAQ:LENZ) Sees Strong Trading Volume - Should You Buy?March 13, 2025 | marketbeat.comLENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025March 11, 2025 | globenewswire.com Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address LENZ Media Mentions By Week LENZ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LENZ News Sentiment▼1.270.64▲Average Medical News Sentiment LENZ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LENZ Articles This Week▼62▲LENZ Articles Average Week Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SRRK News Today AKRO News Today VKTX News Today XENE News Today CPRX News Today MOR News Today PTGX News Today HCM News Today IMVT News Today APLS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LENZ) was last updated on 5/7/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LENZ Stock Free LENZ Stock Alerts